Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma
This trial is active, not recruiting.
|Treatments||radiofrequency ablation, cytokine-induced killer cells|
|Phase||phase 2/phase 3|
|Sponsor||The First People's Hospital of Changzhou|
|Start date||July 2012|
|End date||July 2030|
|Trial size||50 participants|
|Trial identifier||NCT02482454, chol001|
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.
|Endpoint classification||efficacy study|
|Intervention model||parallel assignment|
time frame: 1 year
time frame: 4 weeks
Male or female participants from 30 years up to 80 years old.
- Patients with histologically confirmed cholangiocarcinoma
- Primary lesions (cholangiocarcinoma) are not resected
- Serum bilirubin level of 2.0 mg/dl or less.
- Performance status of 0 or 1.
- Expected survival of 1 year or more.
- Informed consent from the patient.
- With extrahepatic metastases
- With other neoplastic disease that is measurable or being treated other than cholangiocarcinoma.
|Official title||Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma|
|Description||The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cholangiocarcinoma.|
Call for more information